AI assistant
Summit Therapeutics Inc. — Director's Dealing 2025
May 2, 2025
30436_dirs_2025-05-01_077f717b-8878-4fd5-8053-7009d8eafde6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2025-04-29
Reporting Person: Anand Bhaskar (Chief Accounting Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-04-29 | Stock Option (right to buy) | $3.85 | A | 600000 | Acquired | 2034-04-02 | Common Stock (600000) | Direct |
| 2025-04-29 | Stock Option (right to buy) | $17.85 | A | 75000 | Acquired | 2035-01-12 | Common Stock (75000) | Direct |
Footnotes
F1: Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest in four equal annual installments, with the first such installment occurring on December 31, 2025.
F2: Not applicable.
F3: Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest in four equal annual installments, with the first such installment occurring on January 12, 2026.